The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D, Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB, Ducray F, Preusser M, Wen PY.

Open source

DOI: 10.1093/neuonc/noae107
Published: 2024-10-01
Container: Neuro Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/neuonc/noae107,
  title = {The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?},
  author = {van den Bent MJ and  French PJ and  Brat D and  Tonn JC and  Touat M and  Ellingson BM and  Young RJ and  Pallud J and  von Deimling A and  Sahm F and  Figarella Branger D and  Huang RY and  Weller M and  Mellinghoff IK and  Cloughsey TF and  Huse JT and  Aldape K and  Reifenberger G and  Youssef G and  Karschnia P and  Noushmehr H and  Peters KB and  Ducray F and  Preusser M and  Wen PY.},
  year = {2024},
  journal = {Neuro Oncol},
  doi = {10.1093/neuonc/noae107},
  url = {https://doi.org/10.1093/neuonc/noae107}
}

RIS

TY  - JOUR
TI  - The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
AU  - van den Bent MJ
AU  -  French PJ
AU  -  Brat D
AU  -  Tonn JC
AU  -  Touat M
AU  -  Ellingson BM
AU  -  Young RJ
AU  -  Pallud J
AU  -  von Deimling A
AU  -  Sahm F
AU  -  Figarella Branger D
AU  -  Huang RY
AU  -  Weller M
AU  -  Mellinghoff IK
AU  -  Cloughsey TF
AU  -  Huse JT
AU  -  Aldape K
AU  -  Reifenberger G
AU  -  Youssef G
AU  -  Karschnia P
AU  -  Noushmehr H
AU  -  Peters KB
AU  -  Ducray F
AU  -  Preusser M
AU  -  Wen PY.
PY  - 2024
JO  - Neuro Oncol
DO  - 10.1093/neuonc/noae107
UR  - https://doi.org/10.1093/neuonc/noae107
ER  -

APA

MJ, V. D. B., PJ, F., D, B., JC, T., M, T., BM, E., RJ, Y., J, P., A, V. D., F, S., D, F. B., RY, H., M, W., IK, M., TF, C., JT, H., K, A., G, R., G, Y., P, K., H, N., KB, P., F, D., M, P., & PY., W. (2024). The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?. Neuro Oncol. https://doi.org/10.1093/neuonc/noae107

Source records

europe-pmc · retrieved 2026-09-25T21:40:05.124Z
hal · retrieved 2026-09-25T21:40:05.173Z